Australia markets closed

Beximco Pharmaceuticals Limited (R2WA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.42000.0000 (0.00%)
As of 08:20AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 447.33M
Enterprise value 498.16M
Trailing P/E 4.20
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.52
Price/book (mrq)0.48
Enterprise value/revenue 0.01
Enterprise value/EBITDA 0.06

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-3.23%
S&P500 52-week change 323.57%
52-week high 30.5300
52-week low 30.3720
50-day moving average 30.4356
200-day moving average 30.4357

Share statistics

Avg vol (3-month) 31.85k
Avg vol (10-day) 31.78k
Shares outstanding 5446.11M
Implied shares outstanding 61.07B
Float 8297.32M
% held by insiders 10.00%
% held by institutions 11.72%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.03
Forward annual dividend yield 47.02%
Trailing annual dividend rate 33.50
Trailing annual dividend yield 3833.33%
5-year average dividend yield 44.04
Payout ratio 429.75%
Dividend date 3N/A
Ex-dividend date 410 Nov 2023
Last split factor 21.1:1
Last split date 323 Nov 2020

Financial highlights

Currency in BDT.

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 12.37%
Operating margin (ttm)17.20%

Management effectiveness

Return on assets (ttm)6.97%
Return on equity (ttm)10.99%

Income statement

Revenue (ttm)43.08B
Revenue per share (ttm)96.58
Quarterly revenue growth (yoy)15.00%
Gross profit (ttm)N/A
EBITDA 9.43B
Net income avi to common (ttm)5.33B
Diluted EPS (ttm)0.1000
Quarterly earnings growth (yoy)43.50%

Balance sheet

Total cash (mrq)1.36B
Total cash per share (mrq)3.05
Total debt (mrq)7.43B
Total debt/equity (mrq)14.73%
Current ratio (mrq)1.80
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)8.37B
Levered free cash flow (ttm)2.57B